New oral anticoagulants ‑ possible extension to other indications (Review)

  • Authors:
    • Crista Loredana Laslo
    • Nicolae Bacalbasa
    • Ana Maria Alexandra Stanescu
    • Mara Carsote
    • Simona Bungau
    • Marius Rus
    • Ovidiu Gabriel Bratu
    • Camelia Cristina Diaconu
  • View Affiliations

  • Published online on: May 5, 2020     https://doi.org/10.3892/etm.2020.8713
  • Pages: 2401-2405
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anticoagulant treatment is necessary in various conditions, with curative or preventive purposes. Until recently, the only oral anticoagulants available have been vitamin K antagonists. To overcome the disadvantages of the antivitamin K oral anticoagulants, new oral anticoagulants (NOACs) have been developed and included in clinical trials. After more than 60 years of using vitamin K antagonists, the introduction of NOACs represent a medical breakthrough, with promising prospects. Due to their promising results and better safety profile, NOACs have become an appealing alternative to vitamin K antagonists in a short period of time. NOACs have been approved for the prevention and treatment of venous thromboembolism and for the prevention of stroke in patients with nonvalvular atrial fibrillation. Starting with postoperative venous thromboprophylaxis after hip replacement surgery, NOACs have been approved also for other clinical situations. Rivaroxaban is the first oral anticoagulant approved to be used in combination with an antiplatelet agent to prevent atherothrombotic events in adults with coronary artery disease and/or peripheral artery disease. However, further investigation is needed to establish which group of patients would benefit most from this medical approach. Furthermore, preliminary studies have shown that NOACs seem to be a reasonable choice of anticoagulation for patients with cancer, but further studies are expected.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Laslo CL, Bacalbasa N, Stanescu AA, Carsote M, Bungau S, Rus M, Bratu OG and Diaconu CC: New oral anticoagulants ‑ possible extension to other indications (Review). Exp Ther Med 20: 2401-2405, 2020
APA
Laslo, C.L., Bacalbasa, N., Stanescu, A.A., Carsote, M., Bungau, S., Rus, M. ... Diaconu, C.C. (2020). New oral anticoagulants ‑ possible extension to other indications (Review). Experimental and Therapeutic Medicine, 20, 2401-2405. https://doi.org/10.3892/etm.2020.8713
MLA
Laslo, C. L., Bacalbasa, N., Stanescu, A. A., Carsote, M., Bungau, S., Rus, M., Bratu, O. G., Diaconu, C. C."New oral anticoagulants ‑ possible extension to other indications (Review)". Experimental and Therapeutic Medicine 20.3 (2020): 2401-2405.
Chicago
Laslo, C. L., Bacalbasa, N., Stanescu, A. A., Carsote, M., Bungau, S., Rus, M., Bratu, O. G., Diaconu, C. C."New oral anticoagulants ‑ possible extension to other indications (Review)". Experimental and Therapeutic Medicine 20, no. 3 (2020): 2401-2405. https://doi.org/10.3892/etm.2020.8713